J
Jazz Pharmaceuticals plc (JAZZ)
NMS – Real vaqt narxi. Valyuta: USD
248.95
+0.97 (0.39%)
Yopilishda: Aug 12, 2026, 3:59 PM EDT
248.95
+0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:13 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
248.95
+0.97 (0.39%)
Yopilishda: Aug 12, 2026, 3:59 PM EDT
248.95
+0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:13 PM EDT
Jazz Pharmaceuticals plc Qo'shma Shtatlar, Evropa va xalqaro miqyosda farmatsevtik mahsulotlarni aniqlaydi, ishlab chiqadi va tijoratlashtiradi. Kompaniya narkolepsiya va idiomatik uyquchanlik (IH) bilan bog'liq katapleksiya yoki haddan tashqari kunduzgi uyquchanlikni (EDS) davolash uchun Xywav; Lennox-Gastaut sindromi (LGS), Dravet sindromi (DS) yoki qo'ziqorinli skleroz kompleksi (TSC) bilan bog'liq tutqanoqlik uchun Epidiolex; o'tkir limfoblastik leykemiya yoki limfoblastik limfomani davolash uchun Rylaze; o'tkir limfoblastik leykemiya va limfoblastik limfomani davolash uchun Enrylaze; platina asosidagi kimyoterapiya yoki undan keyin kasallik rivojlangan metastatik mayda hujayrali o'pka rakini davolash uchun Zepzelca; HER2-pozitiv o't pufagi xavfli o'smalarini davolash uchun Ziihera; H3 K27M mutatsiyasiga ega diffuz midline glioma davolash uchun Modeyso; va og'ir veno-okklyuziv kasallikni davolash uchun Defitelio taklif etadi. Shuningdek, u HER2-pozitiv gastroezofageal adenokarsinoma (GEA) va o't pufagi xavfli o'smalarini (BTC) davolash uchun 3-bosqichli sinovda Zanidatamabni; H3 K27M-mutatsiyali diffuz glioma davolash uchun Dordaviprone; va yangi tashxislangan terapiya bilan bog'liq o'tkir miyeloid leykemiyani davolash uchun Vyxeosni ishlab chiqadi. Bundan tashqari, kompaniya neoad'yuvant va adjuvant ko'krak bezi rakini davolash uchun Zanidatamabni; yuqori xavfli MDS, yangi tashxislangan davolanmagan yuqori xavfli AML bemorlari va genomika bo'yicha tasniflangan De novo oraliq yoki salbiy xavfli AMLni davolash uchun Vyxeosni; va 2-bosqichli klinik sinovlarda bo'lgan feoxromotsitoma va paragangliomani davolash uchun JZP3507ni ishlab chiqmoqda. Shuningdek, u Raf va Ras mutant o'smalarini davolash uchun JZP815ni; qattiq o'smalarda IFN INDUKIN molekulasi uchun JZP898ni; va 1-bosqichli klinik sinovlarda bo'lgan absans epilepsiyani davolash uchun JZP047ni ishlab chiqadi. Kompaniya Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; va AbCellera Biologics Inc. bilan hamkorlik shartnomalariga ega. Jazz Pharmaceuticals plc 2003 yilda tashkil etilgan va shtab-kvartirasi Dublin, Irlandiyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development |
| Mr. Bruce C. Cozadd | Co-Founder & Chairman |
| Mr. John Miller | Senior Vice President of Corporate Strategy |
| Mr. John D. Bluth | Head of Investor Relations |
| Mr. Philip L. Johnson | Executive VP & CFO |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer |
| Ms. Renee D. Gala | President, CEO & Director |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-10 | 8-K | d151973d8k.htm |
| 2026-08-03 | 10-Q | jazz-20260630.htm |
| 2026-07-24 | 8-K | jazz-20260723.htm |
| 2026-07-14 | DEFA14A | a2026agmvoteupdate.htm |
| 2026-06-08 | DEF 14A | jazz-20260605.htm |
| 2026-05-29 | PRE 14A | jazz-20260529.htm |
| 2026-05-29 | 8-K | jazz-20260525.htm |
| 2026-05-05 | 8-K | jazz-20260505.htm |
| 2026-05-05 | 10-Q | jazz-20260331.htm |
| 2026-04-24 | 10-K/A | jazz-20251231.htm |